Microbiome-based informed method to formulate live biotherapeutics

    公开(公告)号:US20200227139A1

    公开(公告)日:2020-07-16

    申请号:US16800702

    申请日:2020-02-25

    IPC分类号: G16B30/20 C12N9/00 A61K35/742

    摘要: Methods of formulating live biotherapeutics are disclosed in which a deficiency or excess of a specific bacterial strain in a person's microbiome is identified by comparing a gene-specific characterization of the person's microbiome against a comprehensive, non-redundant reference gene catalog, and the biotherapeutic is formulated by selecting bacteria to address the deficiency or excess. Embodiments include the formulation of live biotherapeutics for improving the health of a person's vaginal microbiome, i.e. using a vaginal reference gene catalog, and may be suitable for ameliorating, treating, or preventing a malignancy such as a cancer of the female genitourinary system.

    Methods of agent delivery into eggs and embryos of egg-producing aquatic animals for drug screening, agent toxicity assay and production of infertile fish

    公开(公告)号:US10709119B2

    公开(公告)日:2020-07-14

    申请号:US15568729

    申请日:2016-05-17

    摘要: Methods are provided for delivery of at least one agent into egg(s) from an egg-producing aquatic animal including contacting fertilized or unfertilized egg(s) from said egg-producing aquatic animal with the at least one agent in the presence of a guanidine-containing compound capable of enhancing the permeability of the chorion of the egg(s). Methods are provided for the drug screening and compound toxicity assays. Methods are also provided for the production of reproductively sterile fish and aquatic animals for aquaculture, the aquarium trade, and control of invasive species are described. The methods include disruption of gonadal development through the administration of agents that lead to the failure of fertile gonadal development. Agents may be delivered to the eggs directly before the fertilization or post fertilization by contacting eggs in an immersion medium including the agent of interest.

    Small Molecule Lipid II Inhibitors
    94.
    发明申请

    公开(公告)号:US20200216394A1

    公开(公告)日:2020-07-09

    申请号:US16724821

    申请日:2019-12-23

    IPC分类号: C07D213/26 A61P31/04

    摘要: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a generic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

    Apparatus and method for use in analyzing a patient's bowel

    公开(公告)号:US10702204B2

    公开(公告)日:2020-07-07

    申请号:US16139601

    申请日:2018-09-24

    发明人: David J. Vining

    摘要: An apparatus and method are provided for use in studying a patient's bowel which combines recording and analysis of physiologic parameters and patient sensory perception. A pain input detector, a pain transducer, and a processor are provided. A gas pressure transducer and flow meter may also be provided. Output data may be generated to reflect perceived patient pain, volume of gas delivered to the patient's bowel, and bowel pressure. An indication of perceived patient pain is processed by the processor to generate data that may used to validate a scan of a patient or may be used as a diagnostic tool.

    METHODS OF MAKING ACTIVE ANTIBODIES FROM BIOLOGICAL FLUIDS

    公开(公告)号:US20200182883A1

    公开(公告)日:2020-06-11

    申请号:US16302525

    申请日:2017-05-25

    IPC分类号: G01N33/68 C07K16/10 C07K1/22

    摘要: The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deducted amino acid sequence of party vi); and viii) testing the antibody of part vii) for activity.

    Ossicular prosthesis and method and system for manufacturing same

    公开(公告)号:US10646331B2

    公开(公告)日:2020-05-12

    申请号:US15963332

    申请日:2018-04-26

    摘要: Disclosed herein is a customized ossicular prosthesis suitable for treatment of conductive hearing loss due to ossicular chain defects, and a method and system for manufacturing the same. Medical imaging equipment can detect specifically designated landmarks in normal human middle ear ossicles, including significant anatomic differences in those structures. Those anatomic features are used to generate a customized ossicular prosthesis specifically configured for a particular patient's anatomy using 3D printing techniques and devices.